Skip to main
IMDX
IMDX logo

Oncocyte Corp (IMDX) Stock Forecast & Price Target

Oncocyte Corp (IMDX) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insight Molecular Diagnostics Inc is strategically positioned for strong long-term revenue growth due to its innovative portfolio of advanced diagnostic tests aimed at organ transplant monitoring and cancer detection. Management has highlighted a potential expansion of the addressable market by approximately 10-20%, driven by ongoing clinical trials and the anticipated inclusion of reimbursement for various testing indications. Furthermore, the rebranding of its test kits to GraftAssureIQ and GraftAssureDx could enhance market recognition and drive adoption, further contributing to the company's positive outlook.

Bears say

Insight Molecular Diagnostics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to anticipated slow physician adoption of its new diagnostic tests and delays in obtaining insurer coverage for these services. The company is unlikely to generate revenue from its GraftAssureIQ assay until it secures in-vitro diagnostic clearance for GraftAssureDx, projected for mid-2026, indicating a lengthy period without income. Additionally, operational risks, such as increased cash burn and potential dilution from equity offerings, further exacerbate the financial uncertainties surrounding the company's future performance.

Oncocyte Corp (IMDX) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oncocyte Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oncocyte Corp (IMDX) Forecast

Analysts have given Oncocyte Corp (IMDX) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Oncocyte Corp (IMDX) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oncocyte Corp (IMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.